# EDGAR Filing Document

**Accession Number:** 0001129928
**File Stem:** 0001104659-25-075499
**Filing Date:** 2025-8
**Character Count:** 2724
**Document Hash:** e053ee50dc22859ca9e9047d92c1e9aa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-075499.hdr.sgml**: 20250808

**ACCESSION NUMBER**: 0001104659-25-075499

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250808

**FILED AS OF DATE**: 20250808

**DATE AS OF CHANGE**: 20250808

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ONCOLYTICS BIOTECH INC
- **CENTRAL INDEX KEY:** 0001129928
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38512
- **FILM NUMBER:** 251196352

**BUSINESS ADDRESS:**
- **STREET 1:** 804, 322 - 11 AVENUE SW
- **CITY:** CALGARY
- **STATE:** A0
- **ZIP:** T2R 0C5
- **BUSINESS PHONE:** 4036707380

**MAIL ADDRESS:**
- **STREET 1:** 804, 322 - 11 AVENUE SW
- **CITY:** CALGARY
- **STATE:** A0
- **ZIP:** T2R 0C5

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**of the Securities Exchange Act of 1934**

For the month of **August 2025**

Commission File Number **000-38512**

**Oncolytics Biotech Inc.**

*(Translation of registrant's name into English)*

**Suite 804, 322 11th Avenue SW**

**Calgary, Alberta, Canada T2R 0C5**

*(Address of principal executive offices)*

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

**INCORPORATION BY REFERENCE**

Exhibit 99.1 set forth below on this Form 6-K is hereby incorporated by reference as an exhibit to the Registration Statement on Form F-10 of Oncolytics Biotech Inc. (File No. 333-281009), as amended or supplemented.

**DOCUMENTS FILED**

---

| | |
|:---|:---|
| **EXHIBIT** <br> **NUMBER** | **DESCRIPTION** |
| [99.1](https://www.sec.gov/Archives/edgar/data/1129928/000112992825000046/onc-micfinal2025.htm) | [Information Circular, incorporated by reference to Exhibit 99.1 to the registrant's Foreign Issuer Report on Form 6-K as filed with the Commission on July 8, 2025.](https://www.sec.gov/Archives/edgar/data/1129928/000112992825000046/onc-micfinal2025.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Oncolytics Biotech Inc.** <br> (Registrant) | **Oncolytics Biotech Inc.** <br> (Registrant) |
| Date: August 8, 2025 | By: | /s/ Kirk Look |
|  |  | Kirk Look |
|  |  | Chief Financial Officer |

---